BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
Sign in
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence

  Business Intellilgence

Generative Diffusion in Molecular Design

by BiopharmaTrend   •   Nov. 27, 2025

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook

A quick field guide to diffusion-based generators in molecular design—how they work, where they complement transformers, and who is deploying them today.

Last week, Californian drug discovery startup Terray Therapeutics introduced an experimentation-based machine intelligence platform called EMMI. The platform unites the company’s proprietary ultra-dense microarray technology with an AI stack built around its COATI foundation model, which maps chemical representations to respective molecular properties for better scientific understanding. EMMI is designed to guide R&D reasoning and propose molecular candidates with the later refinement and validation. Terray couples a 13-billion-measurement binding dataset with COATI-based diffusion and RL generators, and an uncertainty-aware selection layer, into a closed-loop system that decides not only what to propose but also which molecules are worth the cost of actually making and testing. In 2024, the company released its first latent diffusion-based molecular generator.

Terray’s work in diffusion methods prompted a broader reflection on generative AI in biology. Today, most conversations and publications center on Transformer-based systems, especially large language models (LLMs) and other foundation models (FMs). LLMs make up a major subset of FMs, but whereas language models are trained primarily on textual data like natural language, code, or biological sequences, foundation models extend the paradigm to additional modalities, including images, audio, video, and even multimodal combinations.

Recent meta-reviews in biomedical NLP collectively catalog nearly 300 LLM instances across hundreds of studies. Foundation models are also proliferating, with over 200 tools developed since 2022 in drug discovery alone. In contrast, the literature on diffusion models for biological and chemical applications remains comparatively modest. So far, there have been only a handful of reviews capturing the diffusion generators. Yet despite lower popularity, diffusion architectures are carving out a meaningful and distinctive role in biotech research and industry.

Before diving deeper into their role in biomedicine, let’s briefly review how diffusion models work in general.


In this article: Diffusion Models 101 — With or against Transformers? — Diffusion Models in Biomedicine — Dispersed Players — Diffusion Online Stations — An Afternote


 

To read the rest of this article, upgrade to a BiopharmaTrend Pro subscription.

Gain full access to all of our deep dives and content archives.

 Upgrade to Pro 

Already a member? Sign in here.
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.